Cargando…
A new visual rating scale for Ioflupane imaging in Lewy body disease
BACKGROUND: Dopaminergic loss on (123)I-Ioflupane brain imaging is a recognised biomarker for dementia with Lewy bodies. It is usually assessed using a visual rating scale developed for Parkinson's disease, which may not be optimal for dementia with Lewy bodies, as patterns of dopaminergic loss...
Autores principales: | Lloyd, Jim J., Petrides, George, Donaghy, Paul C., Colloby, Sean J., Attems, Johannes, O'Brien, John T., Roberts, Gemma, Thomas, Alan J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169248/ https://www.ncbi.nlm.nih.gov/pubmed/30268991 http://dx.doi.org/10.1016/j.nicl.2018.09.012 |
Ejemplares similares
-
Diagnostic accuracy of dopaminergic imaging in prodromal dementia with Lewy bodies
por: Thomas, Alan J., et al.
Publicado: (2019) -
Microbleeds in dementia with Lewy bodies
por: Donaghy, Paul C., et al.
Publicado: (2020) -
Accuracy of Cardiac Innervation Scintigraphy for Mild Cognitive Impairment With Lewy Bodies
por: Roberts, Gemma, et al.
Publicado: (2021) -
In vivo nucleus basalis of Meynert degeneration in mild cognitive impairment with Lewy bodies
por: Schumacher, Julia, et al.
Publicado: (2021) -
Clinical and imaging correlates of amyloid deposition in dementia with Lewy bodies
por: Donaghy, Paul C., et al.
Publicado: (2018)